1. Introduction
===============

Constipation is a very common gastrointestinal condition in childhood.^\[[@R1]--[@R3]\]^ It has been estimated that the prevalence of such condition ranges from 3% of all visits to pediatric outpatient clinics to 25% of all visits to pediatric gastroenterologists in USA.^\[[@R1],[@R3]--[@R5]\]^ The other study reported that the median prevalence is 8.9%, varying from 0.7% to 29.6%.^\[[@R3],[@R6]\]^ In China, its prevalence rates were reported as 24.9% in Shanghai, and 29.6% in Hong Kong.^\[[@R7]--[@R8]\]^

Chronic constipation in children can often result in significant abdominal pain, poor appetite, school absenteeism, or even depression for children with such condition, which significantly affect the quality of their life, as well as their families.^\[[@R9]--[@R10]\]^ Thus, producing soft and painless stools help to prevent such condition.^\[[@R10]\]^

Various modalities are utilized to treat chronic constipation. These managements consist of high fiber diet, toilet training, and behavioral therapy, as well as the medication, including the stimulant laxatives (lactulose, polyethylene glycol solution), and lubricants.^\[[@R11]--[@R20]\]^ Of these, lactulose is recommended as one of the most potential candidates for this condition control.^\[[@R21]--[@R23]\]^ However, there is still insufficient evidence of lactulose for Chinese children with chronic constipation. Therefore, this study explored the efficacy and safety of lactulose for the management of Chinese children with chronic constipation.

2. Methods/design
=================

2.1. Ethical approval
---------------------

This study was approved by the ethics committee of Yulin No. 2 Hospital and The People\'s Hospital of Yan'an.

2.2. Study design
-----------------

It was conducted at Yulin No. 2 Hospital and The People\'s Hospital of Yan'an from April 2016 to March 2018. A total of 100 eligible children with chronic constipation were included in this randomized controlled trial. They were equally divided into the treatment group and the placebo group, each group 50 participants. The patients in the treatment group received lactulose, while the subjects in the placebo group were given placebo intervention. Patients in both groups were treated for a total of 6 weeks. All primary and secondary outcomes were measured at baseline and after 6 weeks treatment in this study.

2.3. Patients
-------------

Patients inclusion criteria dictated that,

1.  all included children aged between 2 and 6 years old with a diagnosis of chronic functional constipation (experienced at least 3 months) according to the modification of the Rome II criteria for preschool children ;^\[[@R24]\]^

2.  fulfill at least 2 of the following 4 criteria: a stool frequency \< 3 times weekly for at least 3 months, or fecal incontinence (children who had already acquired toilet skills) ≥2 times weekly for at least 3 months, at least 1 periodic passage of large amount stool every 7 to 30 days, or a palpable mass at abdomen or rectum;

3.  written informed consent was obtained from guardians of each child.

Exclusion criteria included children with organic causes of defecation disorders, suspected gastrointestinal obstruction, abdominal or rectal surgery that might affect the constipation, or any other conditions that cause the chronic constipation, or previously used lactulose or other laxatives, or prebiotics or probiotics or antibiotics 1 month before the study. In addition, children were also excluded if they had severe neurologic or psychiatric, or mental disorders.

2.4. Randomization
------------------

A total of 100 children were randomly divided into the treatment group and the placebo group at a ratio of 1:1, each group 50 children. Randomization schedule was conducted by using of sequential numbers, generating from the statistical analysis system (SAS) package 8.1 (SAS Institute Inc., Cary, NC, USA). Any randomization and allocation information were concealed in opaque sealed envelopes. The patients, investigators, outcome assessors, and data analysts were masked to the treatment allocation information.

2.5. Intervention schedule
--------------------------

Patients in the treatment group received 5 ml lactulose (3.3 g) daily for a total of 6 weeks. The participants in the placebo group underwent placebo, the same size, dose, color, flavor, and appearance as the lactulose in the treatment group. Additionally, subjects in the placebo group also received a total of 6 weeks placebo.

2.6. Outcome measurements
-------------------------

The primary outcome was daily stool frequency. The secondary outcome measurements included stool consistency, measured by the Bristol Stool Form Scale (from 1, hard stools; to 7, liquid stools)^\[[@R25]\]^; abdominal pain (from 0, not at all; to 3, continuous); flatulence (from 0, not at all; to 3, continuous). In addition, any adverse events were also recorded in this study. All outcomes were evaluated at baseline and after 6 weeks of treatment.

3. Statistical analysis
=======================

The data analysis was conducted by using the SAS package 8.1 (SAS Institute Inc., Cary, NC, USA). The sample size was calculated based on the difference in mean stool frequency of 40% between lactulose and placebo, with α = 0.5, β = 0.8. Assuming a 20% drop-out rate, the required sample size of the present study was therefore estimated to be 100 children, with 50 assigned to each group.

All data were analyzed by intention-to-treat (ITT) analysis. The Mann--Whitney *U* test or *t* test was applied to analyze the continuous data. The Pearson chi-square test or Fisher exact test was utilized to analyze the categorical data. The statistical significance level was defined as *P* \< .05.

4. Results
==========

In total, 148 children with chronic constipation were assessed for eligibility in this study (Fig. [1](#F1){ref-type="fig"}). Of these, 48 subjects were excluded. Thus, 100 children were randomly allocated to the treatment group (n = 50), and the placebo group (n = 50). Nine children withdrew from the study because of the lost to follow-up, and consent withdrawn, although all patients entered into the final analysis by using ITT approach.

![Patients flowchart through the study.](medi-97-e13794-g001){#F1}

The baseline characteristics of all included patients in both groups are shown in Table [1](#T1){ref-type="table"}. There were no significant differences in all baseline characteristics between 2 groups.

###### 

Comparison of baseline characteristics.

![](medi-97-e13794-g002)

After 6-weeks treatment, patients in the treatment group did exert better outcomes in daily stool frequency (*P* \< .01, Table [2](#T2){ref-type="table"}), and stool consistency (*P* \< .01, Table [3](#T3){ref-type="table"}), compared with patients in the control group. On the other hand, no significant differences in abdominal pain (*P* = .24, Table [4](#T4){ref-type="table"}), and flatulence (*P* = .44, Table [5](#T5){ref-type="table"}) were found between 2 groups after the 6-week treatment.

###### 

Comparison stool frequency between 2 groups.
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###### 

Comparison of stool consistency between 2 groups.
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###### 

Comparison of abdominal pain between 2 groups.
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###### 

Comparison of flatulence between 2 groups.
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During the 6-week treatment period, no severe adverse events were recorded (Table [6](#T6){ref-type="table"}). No death related to the treatment was documented. No significant differences of all adverse events were detected between 2 groups.

###### 

Comparison of adverse events between 2 groups.
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5. Discussion
=============

Several previous trials have explored the efficacy and safety of lactulose in children with chronic constipation, and have achieved encouraging outcome results.^\[[@R26]--[@R28]\]^ However, all these trials were conducted among the children population from other countries, but not for Chinese children. To our best knowledge, the present randomized controlled trial firstly specifically investigated the efficacy and safety of lactulose in Chinese children with chronic constipation.

The results of the present study showed that lactulose contributed to better treatment outcomes against chronic constipation in Chinese children after 6-weeks of treatment compared with the placebo. Our findings demonstrated the promising efficacy and fairly safety of lactulose for treating Chinese children with chronic constipation.

In the present randomized controlled trial, the primary outcome was daily stool frequency. The secondary outcomes were measured by the stool consistency, abdominal pain, flatulence, and adverse events. After 6-week of treatment, lactulose showed statistically significant increase in the change of mean daily stool frequency (*P* \< .01), and stool consistency (*P* \< .01), compared with the placebo. Moreover, no severe adverse events were detected in lactulose group, and both groups had similar safety profile. These results indicated the promising efficacy of lactulose for treating Chinese children with chronic constipation with safety profile.

The present study has 2 limitations. First, the shortcoming of this study was the missing further follow-up evaluation after the 6-week treatment stopped. Indeed, follow-up of either short- or long-term efficacy of lactulose for the treatment in Chinese children with chronic constipation is still needed to be explored. Second, this study did not evaluate the comprehensive conditions of the subjects did, such as the quality of life, and psychological outcomes.

6. Conclusions
==============

This study found that lactulose can treat Chinese children with chronic constipation effectively and safety. Future studies with longer-term treatment and follow-up evaluation are still needed to be explored.
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